PUBLISHER: The Business Research Company | PRODUCT CODE: 2035849
PUBLISHER: The Business Research Company | PRODUCT CODE: 2035849
Bioprocess automation software consists of specialized computer programs developed to monitor, control, and optimize biological production processes. It facilitates real-time data collection, process analysis, and automated adjustments to sustain optimal conditions, enhance consistency, and improve operational efficiency. Bioprocess automation software helps streamline workflows, minimize human errors, and accelerate the development of biopharmaceutical products.
The essential components of bioprocess automation software include software and services. Software refers to platforms and tools that automate bioprocess workflows, ensuring efficiency, accuracy, and regulatory compliance. These solutions are deployed on-premises, cloud-based, or in hybrid models and serve enterprises of all sizes, including small and medium enterprises and large corporations. Key applications include upstream processing, downstream processing, quality control, manufacturing operations, data management, and others, with end users including pharmaceutical companies, research institutes, contract manufacturing organizations, and others.
Tariffs on imported automation software licenses, sensors, and laboratory instrumentation are impacting the bioprocess automation software market by increasing procurement and implementation costs, particularly affecting cloud-based and IoT-integrated software solutions. Regions such as North America, Europe, and Asia-Pacific, which depend on imported components and software, are most affected. While tariffs increase operational expenses, they also promote domestic software development, local manufacturing of compatible instruments, and innovation in cost-effective and efficient automation solutions, offering long-term market advantages.
The bioprocess automation software market research report is one of a series of new reports from The Business Research Company that provides bioprocess automation software market statistics, including bioprocess automation software industry global market size, regional shares, competitors with a bioprocess automation software market share, detailed bioprocess automation software market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess automation software industry. This bioprocess automation software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bioprocess automation software market size has grown rapidly in recent years. It will grow from $3.07 billion in 2025 to $3.44 billion in 2026 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to increasing demand for biopharmaceutical products, adoption of automated process control systems, rising need for process consistency, expansion of research and development activities, growing adoption of laboratory information management systems.
The bioprocess automation software market size is expected to see rapid growth in the next few years. It will grow to $5.45 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to growing deployment of AI-driven process optimization, increasing integration with cloud-based data management, rising demand for predictive bioprocess monitoring, expansion of hybrid automation solutions, growing focus on reducing human error and operational costs. Major trends in the forecast period include increasing adoption of cloud-based bioprocess automation software, rising demand for real-time data analytics in bioprocessing, growing integration with IoT-enabled bioreactors, expansion of quality and regulatory compliance automation, rising focus on upstream and downstream process optimization.
The rising investment in research and development is expected to drive the growth of the bioprocess automation software market in the near future. Research and development encompasses systematic activities undertaken by organizations and institutions to generate new knowledge, enhance existing products, or create innovative technologies and processes. The surge in R&D investment is largely influenced by the growing demand for biologics and advanced therapeutics, as pharmaceutical and biotechnology companies dedicate significant resources to developing complex biopharmaceutical products that require sophisticated manufacturing processes. Increased R&D spending boosts the demand for bioprocess automation software by necessitating advanced digital systems to manage increasingly intricate biomanufacturing workflows, ensure regulatory compliance, and optimize production efficiency across both research and commercial operations. For instance, in February 2025, the National Center for Science and Engineering Statistics (NCSES), a US government statistical agency, reported that U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, reflecting a $48 billion rise. Therefore, the growing investment in research and development is driving the expansion of the bioprocess automation software market.
Key companies operating in the bioprocess automation software market are focusing on adopting strategic collaborations to deliver integrated digital solutions that improve process control, data connectivity, and manufacturing efficiency. Strategic collaborations are structured alliances where organizations work together to pursue common objectives by combining their expertise and capabilities, helping businesses drive innovation, enter new markets, share risks, and strengthen their competitive position without undergoing a merger. For example, in June 2024, AGU, a Germany-based provider of bioprocess automation technologies, partnered with Genedata, a Switzerland-based bioinformatics software company, to integrate AGU's SmrtLine Data Cockpit middleware with the Genedata Biopharma Platform, creating a unified bioprocess automation solution that automates instrument data capture, streamlines data flow in GxP-regulated environments, and aims to enhance efficiency and data integrity for biopharma process development.
In August 2024, Danaher Corporation, a healthcare company based in the US, acquired Genedata AG for an undisclosed sum. Through this acquisition, Danaher Corporation expands its life sciences portfolio by incorporating Genedata's bioprocess automation software to streamline, digitalize, and optimize biopharmaceutical research, development, and manufacturing workflows. Genedata AG, headquartered in Switzerland, is a company that provides bioprocess automation software through its Genedata Bioprocess platform.
Major companies operating in the bioprocess automation software market are Honeywell International Inc., Danaher Corporation, Siemens Healthineers AG, Parker Hannifin Corporation, Rockwell Automation Inc., Yokogawa Electric Corporation, Getinge AB, Waters Corporation, Bioengineering AG, Eppendorf SE, Tecan Group Ltd., Repligen Corporation, Hamilton Company, Pierre Guerin SAS, Inscripta Inc., INFORS HT AG, Automated Control Concepts Inc., Synthace Ltd., Flownamics Inc., ILS Automation Inc., and PendoTECH Inc.
North America was the largest region in the bioprocess automation software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess automation software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the bioprocess automation software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The bioprocess automation software market consists of revenues earned by entities by providing services such as system integration services, real-time process monitoring and control, data analytics and visualization services, regulatory compliance, and electronic batch record (EBR) management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bioprocess Automation Software Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses bioprocess automation software market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for bioprocess automation software ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bioprocess automation software market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.